Soleno Therapeutics (SLNO) Cash from Operations (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Cash from Operations of 25980000.0 for Q1 2026, up 179.32% year-over-year from 9301046.74 in Q1 2025, and down 46.66% quarter-over-quarter from 48706000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Cash from Operations (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Cash from Operations for 14 consecutive years, with 25980000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 179.32% year-over-year to 25980000.0; the TTM figure through Mar 2026 stood at 105532000.0 (up 218.15% YoY), while the FY2025 annual figure was 46800000.0, up 167.73% from the prior year.
- Cash from Operations retreated to 25980000.0 in Q1 2026 per SLNO's latest filing, from 48706000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 48706000.0 in Q4 2025 and bottomed at 32752000.0 in Q1 2025.
- Historically, Cash from Operations has averaged 2472764.71 across 5 years, with a median of 6332000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations sank 279.97% — and 2025, when it jumped 391.4%.
- Soleno Therapeutics' Cash from Operations stood at 5143000.0 in 2022, then dropped by 22.77% to 6314000.0 in 2023, then tumbled by 279.97% to 23991000.0 in 2024, then jumped by 303.02% to 48706000.0 in 2025, then sank by 46.66% to 25980000.0 in 2026.
- Business Quant data shows SLNO's Cash from Operations at 25980000.0 in Q1 2026, 48706000.0 in Q4 2025, and 43494000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 25.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.98 Mn |
| Mar 31, 2026 | 25.98 Mn |
| Dec 31, 2025 | 48.71 Mn |
| Dec 31, 2025 | 48.71 Mn |
| Sep 30, 2025 | 43.49 Mn |
| Sep 30, 2025 | 43.49 Mn |
| Jun 30, 2025 | -12.65 Mn |
| Jun 30, 2025 | -12.65 Mn |
| Mar 31, 2025 | -32.75 Mn |
| Mar 31, 2025 | -32.75 Mn |
| Dec 31, 2024 | -23.99 Mn |
| Dec 31, 2024 | -23.99 Mn |
| Sep 30, 2024 | -14.93 Mn |
| Sep 30, 2024 | -14.93 Mn |
| Jun 30, 2024 | -17.65 Mn |
| Jun 30, 2024 | -17.65 Mn |
| Mar 31, 2024 | -12.53 Mn |
| Mar 31, 2024 | -12.53 Mn |
| Dec 31, 2023 | -6.31 Mn |
| Dec 31, 2023 | -6.31 Mn |